

October 25th, 1972

William R. Darrow, M.D., Ph.D.,  
Pharmaceuticals Division,  
CIBA-GEIGY Corporation,  
Summit, New Jersey 07901.

Dear Doctor Darrow,

I have discussed your request of October 16th with my associates, Drs. Gaztanaga, Abrams and Jones.

It is difficult for us to accept your suggestion and delete all mention of the compound GP 41299 from our report. As we see it, there are two possibilities. If we are correct in expanding the clinical applications of this compound, it would serve neither our interests, nor the methods which we used to make this prediction, if the report became lost in the world literature because it could not be identified.

If our prediction is in error, we can only know this if the compound is assessed by others for its anti-anxiety and anti-depressant potency, and this will only be done if we stimulate the interest of other investigators as well as the research staff at CIBA-GEIGY.

For these reasons we can not accept the suggestion made in your letter. We hope that publication will serve to stimulate further interest in GP 41299 and thereby increase the study and the sale of this compound.

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry

MF/ij